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Abstract
Obesity and metabolic syndrome are considered as re-
sponsible for a condition known as the non-alcoholic 
fatty liver disease that goes from simple accumulation of 
triglycerides to hepatic inflammation and may progress to 
cirrhosis. Patients with obesity also have an increased risk 
of primary liver malignancies and increased body mass 
index is a predictor of decompensation of liver cirrhosis. 
Sarcopenic obesity confers a risk of physical impairment 
and disability that is significantly higher than the risk 
induced by each of the two conditions alone as it has 
been shown to be an independent risk factor for chronic 
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liver disease in patients with obesity and a prognostic 
negative marker for the evolution of liver cirrhosis and 
the results of liver transplantation. Cirrhotic patients with 
obesity are at high risk for depletion of various fat-soluble, 
water-soluble vitamins and trace elements and should 
be supplemented appropriately. Diet, physical activity 
and protein intake should be carefully monitored in these 
fragile patients according to recent recommendations. 
Bariatric surgery is sporadically used in patients with 
morbid obesity and cirrhosis also in the setting of liver 
transplantation. The risk of sarcopenia, micronutrient 
status, and the recommended supplementation in 
patients with obesity and cirrhosis are discussed in this 
review. Furthermore, the indications and contraindications 
of bariatric surgery-induced weight loss in the cirrhotic 
patient with obesity are discussed.
Key words: Obesity; Cirrhosis; Sarcopenia; Malnutrition; 
Bariatric surgery
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Obesity is a frequent cause of chronic liver 
disease that can progress to cirrhosis. Cirrhotic patients 
with obesity frequently have alterations in specific aspects 
of nutritional status, such as poor protein intake and micro-
nutrient deficiencies. Diet, physical activity and protein 
intake should be carefully monitored. Bariatric surgery 
may be an option in the management of patients with 
morbid obesity and cirrhosis also in the setting of liver 
transplantation but scientific evidence is still scarce.
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INTRODUCTION
Liver cirrhosis and obesity: Definitions and epidemiology
Obesity is associated with many adverse consequences 
for health and is closely related to insulin resistance, 
dyslipidemia, and hypertension. Non-alcoholic fatty liver 
disease (NAFLD) represents the hepatic manifestation 
of metabolic syndrome and is intimately related to the 
chronic intrahepatic inflammation that, in turn, is linked 
to adiposity and insulin resistance. Defined as a fatty 
infiltration of the liver exceeding 5% at histology in 
the absence of previous or ongoing significant alcohol 
consumption[1] and/or drug and/or virus infection, NAFLD 
includes a wide spectrum of histopathological alterations 
ranging from simple steatosis (Figure 1A) to non-alcoholic 
steatohepatitis (NASH) (Figure 1B) and cirrhosis (Figure 
1C) with end-stage liver disease. Furthermore, NAFLD 
has been also shown to increase the risk of primary 
liver malignancies such as hepatocellular carcinoma 
(HCC)[2-4]. However, the vast majority of patients with 
NAFLD will not progress as only a minority of those 
with NASH (3%-5%)[5] are at a high risk of developing 
chronic liver disease complications. In patients with 
NASH, 11% develop cirrhosis and approximately 40% 
of patients die within 15 years from any cause (of which 
7.3% are due to liver-related complications, especially 
in those with advanced fibrosis or cirrhosis)[6]. Obesity 
and the chronic inflammation associated with it also have 
a negative effect on health. Excessive adipose tissue 
leads to an increased production of adipokines (such as 
IL-6, TNFa, monocyte chemoattracting protein-1, and 
plasminogen activator inhibitor-1) with proinflammatory, 
pro-fibrogenic, pro-angiogenic, and pro-oxidant effects 
on several tissues. Few data exist regarding the epi-
demiological and clinical impact of obesity in patients with 
pre-existent liver disease, however, obesity is considered 
an independent risk factor for the presence of severe 
fibrosis, fibrosis progression, and cirrhosis[7,8]. Several 
population-based studies have identified obesity as an 
independent risk factor for alcohol-induced liver damage. 
Indeed, ethanol influences the adipose tissue production 
of hormones and cytokines, and excess adiposity induces 
an exacerbation of the proinflammatory state. However, 
it is still unclear whether the hepatotoxic consequences of 
obesity and ethanol ingestion are additive or synergistic. 
The DIONYSOS study clearly showed a synergistic effect 
between alcohol consumption and elevated body mass 
index (BMI) on hepatic steatosis in a large cohort of 
subjects in Northern Italy[9]. The prevalence of hepatic 
steatosis determined by ultrasonography was increased 
to 46% in subjects with a daily intake of > 60 g of 
alcohol and to 76% in patients with obesity compared to 
lean controls who only revealed hepatic steatosis in 16% 
of cases. Moreover, in individuals with obesity drinking > 
60 g of alcohol per day, steatosis was found at an even 
higher level of 95% and the relative risk of cirrhosis 
increased more than six-fold in women with obesity and 
alcohol consumption (> 150 g/wk) vs normal weight and 
drinking < 70 g/wk women.  Ekstedt et al[10] found an 
accelerated progression of fibrosis in patients with NAFLD 
who drank moderate amounts of alcohol (up to 140 
g/wk). Liu et al[11] analyzed more than 1 million middle-
aged women in the UK and reported that in women with 
obesity who drank > 150 g of alcohol/week, the relative 
risk of cirrhosis increased more than six fold.
In patients with chronic hepatitis C virus (HCV)-related 
liver disease and severe liver fibrosis or compensated 
cirrhosis, up to 43% had obesity, and 32% were over-
weight. Each quartile increase in BMI is associated with 
a 14% increase in the risk of clinical events in the follow-
up (worsening of liver fibrosis or decompensation of 
cirrhosis over 3.5 years of follow-up)[12]. Among obesity-
related variables, the severity of insulin resistance and 
the histological grade of steatosis appeared as the factors 
more tightly associated with the progression of liver 
disease. Contrarily, weight loss is indeed beneficial in pa-
tients with advanced chronic liver disease, reducing the 
progression of fibrosis and cirrhosis[13,14].
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Berzigotti et al[13,14] demonstrate that increased BMI 
is a strong predictor of decompensation in patients with 
compensated cirrhosis of various etiologies, independent 
of other previously described predictors such as albumin 
and portal hypertension. More specifically, clinical de-
compensation of cirrhosis (ascites, encephalopathy, or 
jaundice) developed in 14% of patients with normal 
weight, in 31% of overweight patients, and in 43% of 
patients with obesity. Obesity also negatively impacts 
portal hypertension. Indeed, when comparing the results 
after a 1-year course of timolol or a placebo, portal hyper-
tension was reduced only in patients who were of normal 
weight or overweight, whereas patients with obesity 
showed a significant increase.
Even in patients with end-stage liver disease and, 
therefore, awaiting liver transplantation (LT), obesity 
could worsen the prognosis. Recent data suggest that 
in these patients, obesity increases substantially (HR = 
13.1), independently and significantly (p = 0.016) the 
risk of portal vein thrombosis[15], which may render the 
transplantation technically more difficult and increase the 
risk of portal thrombosis recurrence. Indeed, obesity is 
considered as a risk factor for venous thromboembolism 
as well as thrombosis of the hepatic artery[16]. The 
proinflammatory, prothrombotic, and hypofibrinolytic 
milieu patients with obesity may be responsible for the 
local thrombophilia that favors portal vein thrombosis. 
Concerning perioperative LT complications, operative 
time, blood product usage, length of stay in the inten-
sive care unit, infectious complications, and biliary com-
plications requiring intervention have been shown to be 
higher in recipients with obesity[17]. Despite the increased 
technical operative challenges and medical complexities 
associated with recipients with obesity, morbid obesity 
in itself should not be an absolute contraindication to LT 
as these patients have reasonable long-term outcomes. 
Although the complex interplay between obesity and 
cirrhosis is far from elucidated, undoubtedly alcohol, 
viral hepatitis, and obesity appear to be a dangerous 
combination. General impact of obesity on liver patho-
physiology are summarized in Table 1. 
RISK OF SARCOPENIA IN PATIENTS 
WITH OBESITY AND CIRRHOSIS
Sarcopenia is a syndrome characterized by progressive 
and generalized loss of skeletal muscle mass and 
strength with a risk of adverse outcomes such as physical 
disability, poor quality of life, and death[18]. The profound 
negative clinical impact of low skeletal muscle mass 
and function was originally described in the elderly, but 
its role is now unequivocally emerging in many chronic 
progressive diseases, such as chronic kidney disease, 
chronic heart failure, chronic pulmonary insufficiency, and 
type 2 diabetes[18]. Recent evidence suggests that low 
muscle mass and function may have a similar negative 
impact in obesity despite the potential difficulties in identi-
fying and defining muscle changes within the obese 
phenotype[19]. Whatever the definition, the coexistence 
of sarcopenia and obesity in the same patient, now 
indicated as “sarcopenic obesity”, confers a risk of phy-
sical impairment and disability that is significantly higher 
than the risk induced by each of the two conditions 
alone[19-21]. The precise determination of body muscle 
and body mass fat requires the use of dual energy X-ray 
absorptiometry (DXA), but an estimation can be ob-
tained at the clinical level with the use of bioimpedance 
analysis (BIA) or anthropometric measurements[18]. In 
this section, the role of sarcopenic obesity as a prognostic 
factor in patients with liver chronic disease will be briefly 
elucidated. The problem will be analyzed according to 
two different perspectives. First, the possible role played 
by sarcopenia as an independent risk factor for the 
occurrence of liver diseases in patients with obesity will 
be discussed and, second, the significance of sarcopenia 
as a negative prognostic marker for disease progression 
and death in patients with obesity and advanced liver 
disease will be addressed.
Sarcopenia as an independent risk factor for chronic 
liver disease in patients with obesity
As already mentioned above, NAFLD is today the most 
common liver disorder in Western countries and it is 
becoming the leading cause of chronic liver disease and 
cirrhosis[22]. Visceral obesity and related metabolic dis-
orders, insulin resistance, in particular, are considered 
the most relevant risk factors for NAFLD occurrence and 
progression[22]. Recent evidence suggests, however, 
that the prevalence of NAFLD and its severity could 
be independently and negatively affected also by the 
coexistence of sarcopenia in the clinical picture, with 
sarcopenic obesity being both an independent risk factor 
for NAFLD and a marker for its progression to the more 
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Figure 1  Non-alcoholic fatty liver disease and hepatic histopathological alterations. NAFLD includes a wide spectrum of histopathological alterations ranging 
from simple steatosis (A) to non-alcoholic steatohepatitis (B) and cirrhosis (C). NAFLD: Non-alcoholic fatty liver disease.
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with normal muscle mass. Moreover, the association 
between sarcopenia retained its significance also after 
adjustment for all these potential confounding factors[24]. 
More recently, Lee et al[25] tested the association between 
sarcopenia and progression of NALFD by analyzing the 
degree of liver fibrosis in the KNHANES population. 
NAFLD was identified in 2761 (28.5%) of 9676 subjects 
and sarcopenia was identified in 337 of the subjects with 
NAFLD (12.2%). In subjects with NAFLD, sarcopenia 
was significantly and independently associated with 
a higher level of liver fibrosis. The authors concluded 
that sarcopenia was associated with significant liver 
fibrosis in subjects with NAFLD, and this association was 
independent of obesity and insulin resistance[25]. 
The independent and additive role of reduced skel-
etal muscle mass and increased visceral fat mass in 
increasing the risk of the onset of NAFLD, and in serving 
as important factors involved in the progression from 
simple steatosis to liver fibrosis, has been recently con-
firmed in an independent Japanese sample[26]. Taking 
into consideration the limitation of these studies and the 
caveats in extrapolating these data to the Caucasian 
population, the association of sarcopenia with visceral 
obesity and insulin resistance is now considered an 
important risk factor for NAFLD, which further accelerates 
its progression to more advanced life-threatening stages.
Sarcopenia as a prognostic negative marker in the 
cirrhotic patient with obesity
As shown in Figure 2, cirrhotic patients with obesity 
frequently have a combined loss of skeletal muscle 
and gain of adipose tissue, culminating in the condition 
known as “sarcopenic obesity.” Sarcopenia in cirrhotic 
patients has been associated with increased mortality, 
sepsis complications, hyperammonemia, overt hepatic 
encephalopathy (HE), and an increased length of hos-
pital stay after LT[27]. The prognostic impact of the co-
existence of sarcopenia and obesity in patients with 
chronic liver disease has been analyzed recently in a 
few studies. Montano-Loza et al[28] evaluated the fre-
quencies of sarcopenia and sarcopenic obesity in a 
cohort of 457 cirrhotic patients evaluated for LT, aiming 
to establish the impact of these muscular abnormalities 
on the prognosis of cirrhotic patients. In this sample, 
sarcopenia was present in 43% and sarcopenic obesity 
in 20% of patients. Both patients with sarcopenia and 
with sarcopenic obesity had worse median survival 
than patients without muscular abnormalities[28]. Hara 
et al[29] evaluated the independent prognostic impact 
of skeletal muscle mass and visceral fat accumulation 
in 161 patients with cirrhosis. Patients with sarcopenia 
or sarcopenic obesity both had a poor prognosis, and 
this difference was pronounced in the subset of patients 
classified as Child-Pugh class A. However, the group 
with the worst prognosis was represented by patients 
having sarcopenic obesity[29]. This latter observation 
seems to confirm that the coexistence of visceral obesity 
and sarcopenia could be considered the worst clinical 
advanced stages and cirrhosis[23]. 
Significant information about the role of sarcopenia 
in chronic liver disease was produced in an analysis 
of data from the Korea National Health and Nutrition 
Examination Survey (KNHANES). KNHANES includes a 
nationwide cross-sectional cohort with a representative 
sample of the Korean population and is conducted an-
nually to assess health and nutritional status. Hong 
et al[24], by analyzing 452 apparently healthy adults in 
the Korean Obesity Sarcopenic Study, demonstrated a 
higher risk of NAFLD in individuals with lower muscle 
mass compared to a control group. Individuals with 
sarcopenia had more body fat mass, more components 
of the metabolic syndrome, and higher levels of low-grade 
systemic inflammation compared with those of people 
Pathologies Obesity
Hepatic steatosis[9]  Increased1
Cirrhosis[11]  Increased1
Hepatoxicity[9]  Increased1
Liver primary tumors (as hepatocarcinoma)[2-4]  Increased2
Chronic hepatitis C progression[12] Increased
Decompensation of cirrhotic patients[13,14] Increased
Portal hypertension[13,14] Increased
3Risk of post-operative complications after LT[15-17] Increased
Table 1  Impact of obesity on liver pathophysiology
1Mostly if associated to alcohol ingestion; 2Mostly if associated to non-
alcoholic fatty liver disease (NAFLD); 3Thromboembolism, infectious and 
biliary complications. LT: Liver transplantation.
Increased mortality
Sepsis complications
Hyperammonemia
Overt hepatic encephalopathy
Increased length of hospital stay after liver transplantation
Cirrhotic patient with obesity
Loss
Skeletal muscle Adipose tissue
Sarcopenic obesity
Figure 2  Sarcopenia as a prognostic negative marker in the cirrhotic 
patient with obesity. Cirrhotic patients with obesity frequently have a combined 
loss of skeletal muscle and gain of adipose tissue, culminating in the condition 
known as “sarcopenic obesity”. Sarcopenia in cirrhotic patients has been 
associated with increased mortality, sepsis complications, hyperammonemia, 
overt hepatic encephalopathy, and an increased length of hospital stay after 
liver transplantation.
Gain
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situation for a patient with cirrhosis. Muscle wasting and 
fatty muscle infiltration in cirrhotic patients are part of the 
frailty complex present in these patients, characterized as 
decreased reserve and resistance to stressors, resulting 
from cumulative declines across multiple physiologic 
systems and predisposition to poor outcomes[28].
The prognostic negative role of sarcopenia and obe-
sity could have an impact also in LT. Sarcopenia and 
sarcopenic obesity are seen in a significant number 
of patients with cirrhosis undergoing liver transplant 
evaluation, particularly in patients with NASH[30]. Pre-
transplant sarcopenia is widely recognized as associated 
with short-term survival after living donor LT[31]. The 
question of whether the coexistence of obesity and 
sarcopenia could impose additional risk after LT over that 
imposed by sarcopenia alone is still debated. Hammad 
et al[32] evaluated 200 patients undergoing adult-to-adult 
living donor LT and classified them into four subgroups: 
sarcopenic overweight, sarcopenic non-overweight, 
non-sarcopenic overweight, and non-sarcopenic non-
overweight. Sarcopenic patients had a higher incidence 
of postoperative bacteremia and major postoperative 
complications, and poorer overall post-transplant sur-
vival than non-sarcopenic patients. Overweight reci-
pients had a significantly higher overall survival rate 
than non-overweight patients. In contrast, sarcopenic 
non-overweight subjects had a higher incidence of 
postoperative bacteremia, and major postoperative com-
plications compared with the sarcopenic overweight sub-
group and possessed the poorest overall survival among 
the four recipient subgroups. Thus, this study indicates 
that a preoperative sarcopenic overweight status does 
not confer additional significant morbidity or mortality 
risks than the stand-alone sarcopenia in living donor LT. 
The study was however mostly confined to patients who 
were overweight and does not address specifically the 
impact of obesity itself[32]. On the other hand, obesity 
presents important medical and surgical challenges 
during and after a liver transplant. Specifically, obesity 
is associated with an increased incidence of wound 
infections, wound dehiscence, biliary complications, and 
overall infection[33].
Sarcopenic obesity could represent an important 
clinical problem also for long-term survival after LT. 
Sarcopenia tends to persist after transplantation[30,31], 
possibly as the consequence of insufficient physical 
exercise or use of immunosuppressive agents that 
impair skeletal muscle growth and protein accretion[30], 
whereas body fat normally increased as a result of better 
nutrition and the regression of the hypermetabolic state 
related to the pre-transplant chronic disease state[34]. 
This double phenomenon paves the way to sarcopenic 
obesity. Schütz et al[35] analyzed body composition 
in patients after liver and kidney transplantation and 
patients with liver cirrhosis or on chronic hemodialysis 
and demonstrated that, despite excellent graft function, 
many long-term liver or kidney transplant survivors 
exhibit a phenotype of sarcopenic obesity with increased 
fat but low muscle mass[35]. Choudhary et al[36] evaluated 
82 living donor liver transplant recipients with at least 12 
mo of follow-up. Post-transplant sarcopenic obesity was 
present in 88%, and metabolic syndrome was present in 
52% of recipients with no significant difference among 
liver failure etiologies. Patients with sarcopenic obesity 
had a significantly higher BMI and significantly higher 
prevalence of metabolic syndrome when compared to 
patients without sarcopenic obesity[36]. Thus, the weight 
gain frequently observed after LT could contribute to 
the creation of a novel group of patients with sarcopenic 
obesity and associated metabolic derangements. 
MICRONUTRIENT STATUS AND 
RECOMMENDED SUPPLEMENTATION 
IN PATIENTS WITH OBESITY AND 
CIRRHOSIS
Micronutrient deficiencies of fat-soluble and water-
soluble vitamins as well as minerals are highly common 
in end-stage liver disease. Therefore, a periodical nutri-
tional and clinical assessment should be performed to 
test micronutrient serum levels, estimating adequate 
nutritional intake and paying attention to clinical signs of 
vitamins and minerals deficiencies. Fat-soluble vitamin 
(A, D, E, and K) deficiencies and other free radical sca-
vengers, such as carotenoids are likely to develop in 
liver disease due to reduced oral intake, malabsorption, 
and/or hepatic effects involving the reduced synthesis 
of carrier and transfer proteins, cholestasis and bacterial 
overgrowth[37,38].  
Deficiencies in water-soluble vitamins, leading to 
neuropsychiatric symptoms, may stem from diminished 
hepatic storage, inadequate diet, alcoholism, medications, 
and chronic renal failure[37]. The most prevalent and sig-
nificant deficiencies are discussed below, beginning with 
vitamin D deficiency, which is almost universal and also 
related with obesity.
Vitamin D deficiency (VDD, < 50 nmol/L; < 20 ng/mL) 
is a worldwide pandemic, reported in more than half of 
the general adult population[39-42]. Specifically, VDD is 
widespread among patients with chronic liver disease, 
with prevalence described between 70%-90%[40,43-49], 
while the prevalence of vitamin D insufficiency (< 
75 nmol/L; < 30 ng/mL) is almost universal[49]. For 
example, among 202 adults before LT, 84% were 
25(OH)D deficient and 77% had low 1,25(OH)2D, 
whereas 3 mo following transplantation, both increased 
significantly but to a lesser extent for 1,25(OH)2D[50]. 
Moreover, the severity of VDD is positively correlated with 
the severity of liver disease[44-47]. In cirrhotic patients, 
significant correlations were found between vitamin 
D levels and the degree of liver dysfunction, whether 
expressed as Child-Pugh stages A-C, MELD score, or 
liver stiffness evaluated by transient elastography[44,45]. 
In epidemiologic studies, VDD has been demonstrated to 
be a predictor of liver disease morbidity and mortality. In 
a Danish population-based sample of over 2500 middle-
Schiavo L et al . Nutrition in the patients with obesity and cirrhosis
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aged subjects followed prospectively for a median follow-
up period of 16.5 years, lower serum 25(OH)D levels 
were independently associated with higher incidence 
of fatal and non-fatal liver disease[51]. Similarly, in 
another prospective study with 22 years follow-up[52], 
those with a higher serum 25(OH) vitamin D had lower 
chronic liver disease mortality. Among cirrhotic patients, 
VDD was found to be an independent risk factor for 
mortality[43,45]. With the increasing prevalence of obesity 
and NAFLD-related cirrhosis, attention should be paid 
to the cirrhotic patient with obesity. An association 
between VDD and obesity has also been suggested. 
Since vitamin D is a lipophilic molecule it is selectively 
deposited in subcutaneous and visceral adipose tissue. 
This sequestration leads to a reduction of its availability 
for hydroxylation[40,41,53,54]. In addition, an independent 
association was also observed between VDD and insulin 
resistance[55,56], the metabolic syndrome as a whole[57], 
and type 2 diabetes or prediabetes, after adjusting for 
multiple confounders including BMI[55,56,58,59]. In contrast, 
some studies failed to show such associations once 
adiposity is adjusted for[60,61] or any significant association 
between markers of insulin resistance and 25(OH)D 
serum levels[62,63]. NAFLD by itself has been suggested 
to be associated with VDD, but the independence of 
this association from body fat mass is controversial. The 
association between a diagnosis of NAFLD and lower 
serum 25(OH)D levels compared to healthy controls was 
demonstrated in several studies[64-67], however, NAFLD 
was biopsy-proven in only two of the studies[64,65]. In 
addition, significantly higher levels of 25(OH)D were 
observed among patients with steatosis compared to 
patients with NASH[64,65]. In partial agreement, another 
study, describing a sub-analysis of the NASH Clinical 
Research Network (CRN) cohort, found that VDD was 
independently associated with NASH and the presence 
of fibrosis, but not with the degree of steatosis[68]. 
However, while most studies adjusted for BMI or waist 
circumference, a study carefully adjusting for adiposity 
(evaluated by dual-energy X-ray absorptiometry), sug-
gests that there is no relationship between vitamin D 
levels and the amount of liver fat (by Magnetic Reso-
nance Spectroscopy and liver biopsy) or the severity of 
NASH[69].
To summarize, a few possible mechanisms could 
explain VDD among cirrhotic patients with obesity: 
(1) NAFLD as the undelaying cause of cirrhosis; (2) Se-
dentary lifestyle or long standing chronic illness leading 
to reduced exposure to sunlight; (3) Consumption of 
high-caloric “empty” foods, low in mineral and vita-
min content; (4) Increased fat mass which enables 
sequestration of vitamin D in the adipose tissue com-
partment thus lowering plasma concentration; and (5) 
Hepatocellular dysfunction in chronic liver disease which 
may disturb the formation of the active metabolite of 
vitamin D as well as vitamin D-binding proteins. 
Due to the high prevalence of VDD among cirrhotic 
patients, especially those with advanced disease, NAFLD, 
or cholestatic liver diseases[70], it is reasonable to assess 
serum 25(OH)D  levels[71]. The main sources of vitamin 
D are sunlight exposure, food naturally enriched or arti-
ficially fortified with vitamin D, and oral supplements. 
The adequate sunlight exposure is 5-15 min during 
the daytime (10:00 AM-15:00 PM) on a daily basis[40]. 
However, after exposing healthy individuals with obesity 
(BMI > 30 kg/m2) and matched lean control subjects 
(BMI < 25 kg/m2) to whole-body ultraviolet radiation, 
the subjects with obesity showed a 57% lower increase 
in circulating concentrations of vitamin D3, 24 h after 
irradiation[53]. Vitamin D3 can be found abundantly in egg 
yolk and oily fish (e.g. salmon, mackerel, tuna, sardines) 
and vitamin D2 mainly in mushrooms[40,49]. Industrial 
products such as bread, margarine, cereals, or milk may 
be fortified with either vitamin D2 or vitamin D3. Oral 
supplements may contain vitamin D2 or D3 depending 
on the manufacturer and brand[40,49]. However, most 
studies that have evaluated NAFLD and high-dose 
vitamin D supplementation, failed to show improvement 
in liver fat, NASH histology, or liver enzymes[72,73]. Oral 
high-dose vitamin D supplementation administrated to 
subjects with NAFLD and type-2 diabetes for 24 wk, did 
not lead to significant change in hepatic steatosis, HOMA-
IR, or liver enzymes[74]. Similarly, in a pilot prospective 
study, administration of high-dose oral vitamin D3 
supplementation (25000 IU/wk) for 24 wk to 12 non-
cirrhotic patients with biopsy-proven NASH resulted in 
no significant impact on liver histology, liver enzymes, 
insulin resistance, or adipocytokine profile[73]. Conversely, 
some studies, not specific for NAFLD but mostly pre-
diabetic patients, demonstrated improvement in insulin 
sensitivity with vitamin D supplementation[75-77]. Findings 
are also conflicting with regard to the effect of vitamin D 
supplementation in the case of advanced liver disease. In 
a  cohort of advanced decompensated cirrhotic patients 
(Child-Pugh C, score of ≥ 10) randomly assigned to 
vitamin D treatment or a control receiving standard care 
and followed for 6 mo, the survival, as well as Child-
Pugh and MELD scores, were comparable between the 
groups[48]. Nevertheless, supplementation of high-dose 
oral vitamin D resulted in several clinical improvements 
such as an anti-depressant effect among patients with 
chronic liver disease (mainly women)[78], and 60% risk 
reduction for acute rejection among patients after LT[79]. 
In a Cochrane review of vitamin D supplementation for 
chronic liver diseases in adults, including 15 randomized 
clinical trials (RCT) with 1034 participants[80], vitamin D 
supplementation had no beneficial or harmful effects on 
all-cause mortality (OR = 0.69; 95%CI: 0.09 to 5.40), 
and the authors concluded that there is no convincing 
evidence that vitamin D supplementation has a thera-
peutic impact in chronic liver disease. 
There are no guidelines or clear recommendations 
regarding vitamin D supplementation for cirrhotic pa-
tients with obesity. One authoritative paper[49] recom-
mended vitamin D status assessment in all patients with 
chronic liver disease and initiation of supplementation 
with 1000-4000 IU/d of vitamin D3 when 25(OH)D 
levels are under < 50 nmol/L or < 20 ng/mL. The 
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guidelines of a consensus workshop supported by the 
British Association for the Study of the Liver and the 
British Liver Trust, recommends supplementation of 
1 g calcium and 800 IU/D vitamin D to patients with 
chronic liver disease (especially patients with cirrhosis or 
severe cholestasis) as a general preventive treatment for 
osteoporosis along with adequate nutrition monitoring[81]. 
The European Association for the Study of the Liver 
(EASL) recommendation includes supplementation with 
calcium (1000-1200 mg/d) and vitamin D (400-800 IU/d) 
in all patients with cholestatic liver disease for bone loss 
reduction, although the evidence to support this is low[70]. 
Interestingly, in a small study of NAFLD patients, daily 
supplementation with 2000 IU cholecalciferol for 6 mo did 
not correct hypovitaminosis D in the majority of patients 
with NASH compared to those with steatosis, thus a 
higher dose may be needed in NASH or NASH-cirrhosis 
patients but this finding needs further confirmation[82].
Vitamin E (tocopherol) is an inexpensive and well-
tolerated molecule with antioxidant properties. In vitro 
and animal studies have shown that vitamin E amelio-
rates liver necrosis and fibrosis[83], and prevents hepatic 
stellate cell activation[84]. Relevantly for patients with 
obesity and liver disease, high-dose (800 IU/d) long-
term (24 mo) vitamin E treatment among nondiabetic 
NASH patients led to improvement in NASH versus 
placebo but not fibrosis. However, cirrhotic patients were 
excluded from this RCT[85], and thus vitamin E cannot 
be recommended for NASH-cirrhosis or cryptogenic 
cirrhosis patients[86]. Vitamin E status, expressed as 
serum vitamin E/total serum cholesterol ratio, is lower 
among patients with primary biliary cholangitis and pri-
mary sclerosing cholangitis compared to patients with 
either cryptogenic or alcoholic cirrhosis, probably due to 
reduced gastrointestinal absorption[87]. Indeed, a reduced 
concentration of vitamin E and low vitamin E/total cho-
lesterol ratio has been demonstrated in 44% and 64% 
of patients with primary biliary cholangitis and 32% 
and 43% of patients with other chronic cholestatic liver 
diseases, respectively. Serum vitamin E concentration 
and vitamin E/total cholesterol ratio were restored to 
normal by oral or intramuscular supplements of the vita-
min, but not in patients with severe deficiency of vitamin 
E (less than 5 μmol/L and less than 1 μmol/mmol 
total cholesterol)[88]. Generally, carotenoids, as well as 
tocopherols, are major natural protective agents against 
free radical-mediated liver damage. Interestingly, it 
has been demonstrated that patients with cirrhosis (of 
mixed etiologies) have extremely low hepatic levels of 
carotenoids and tocopherols, compared with controls, 
even in the presence of normal serum levels[89]. Similarly, 
retinol, a-tocopherol, and carotenoid plasma levels in 
patients with chronic cholestatic liver disease (primary 
biliary cholangitis and primary sclerosing cholangitis) 
were demonstrated to be significantly lower compared 
to the general population, despite comparable nutritional 
intake, suggesting a role for the malabsorption of fat-
soluble vitamins[38]. Clinical manifestations of vitamin 
E deficiency may include increased platelet aggre-
gation, decreased red blood cell survival, hemolytic 
anemia, decreased serum creatinine with creatinuria, 
and neuronal degeneration[37], but these are not com-
mon[38,87,88].
Zinc is the second most prevalent trace element in 
the body, playing a central role in several metabolic, 
anti-inflammatory and immune response pathways, 
with more than 300 enzymes having zinc ions within 
their catalytic domains[90]. Dietary zinc is prevalent in 
foods which are rich in protein (i.e. red meat, lamb, 
pork, oysters, etc.) and its absorption can be inhibited 
by high consumption of foods rich in phytate, certain 
dietary fibers, and calcium[91,92]. The recommended 
dietary allowance (RDA) of zinc is 8 mg/d for women and 
13 mg/d for men over 19 years old[93]. The liver is the 
main organ of zinc metabolism, however, in chronic liver 
disease, metabolism is altered by inadequate dietary 
intake, protein and amino acid metabolism alterations, 
diminished hepatic extraction, portosystemic shunts, 
impaired absorption (mostly in advanced liver disease), 
and an increase in various inflammatory cytokines[90,94]. 
Moreover, cirrhosis is a catabolic state resulting in muscle 
catabolism leading to increased zinc loss in the urine. 
This urinary loss of zinc is aggravated by the prevalent 
use of diuretics in order to treat edema and ascites[95]. 
Zinc deficiency has many clinical implications in cirrhotic 
patients. One of the major complications in cirrhotic 
patients is HE, presented in 30%-40% of the patients as 
overt encephalopathy (OHE) and in 60%-80% as mild 
cognitive dysfunction (minimal hepatic encephalopathy, 
MHE)[96]. Zinc deficiency results in impaired nitrogen 
metabolism due to the reduced enzymatic activity of 
urea cycle enzymes and decreased muscle glutamine 
synthesis. Furthermore, zinc levels were found to be 
negatively correlated with ammonia serum levels[97,98]. 
These impaired metabolic pathways can be corrected by 
supplementing zinc. In a small preliminary double-blind, 
placebo-controlled trial among patients with cirrhosis, 
hyperammonemia, and hypozincemia, zinc acetate 
preparation at a dose of 150 mg/d for 3 mo decreased 
blood ammonia levels[99]. Indeed, Marchesini et al[100] 
demonstrated in patients with advanced cirrhosis, that 
long-term treatment with zinc supplementation ac-
celerated and improved hepatic conversion of amino 
acids to urea compared with matched controls receiving 
standard treatment. This biochemical improvement was 
associated with a clinical improvement measured by the 
performance in psychometric tests and Child-Pugh score. 
Similar results were observed in an RCT comparing 
zinc supplementation on top of standard treatment 
vs. standard treatment alone (protein-restricted diet, 
branched-chain amino acids, and lactulose) for 6 mo. 
Zinc supplementation improved the physical component 
scale and neuropsychological tests and decreased HE 
grade, Child-Pugh score and blood ammonia levels[101]. 
A significant improvement in neuropsychological tests 
and Child-Pugh score along with ammonia was also 
reported in patients with only MHE after 3 mo of lactu-
lose, antioxidant and zinc therapy vs lactulose therapy 
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alone[102]. Additionally, zinc is a crucial co-factor in the 
process of wound healing since it activates the synthesis 
of collagen and metabolism of nucleic acids. Thus, 
zinc is an essential factor in the restoration of liver par-
enchyma after liver injury or resection and is required 
in large amounts over a short period of time[90,103]. In 
terms of clinical signs for zinc deficiency, skin lesions 
are very prominent, usually an erythematous rash 
or scaly plaques. A unique manifestation is necrolytic 
acral erythema (NAE), associated with zinc deficiency 
in patients with HCV infection[104], expressed on the 
dorsal aspects of the feet and extending to the toes. 
The treatment of NAE must combine oral zinc supple-
mentation and HCV eradication. For more than 70 years, 
hypozincemia has also been associated with impaired 
night vision, initially in alcoholic cirrhosis and later on 
in various liver cirrhosis etiologies[103]. Importantly, one 
of the disturbing manifestations of zinc deficiency is 
an alteration in taste and smell. This may further  ex-
acerbate malnutrition due to reduced intake in the 
cirrhotic patient[37,105,106]. According to expert opinion, 
zinc supplementation can be administrated as a long-
term treatment or at least until zinc blood level is within 
normal range with a recommended dose of 50 mg ele-
mental zinc (220 mg zinc sulfate) once daily, in order to 
avoid copper malabsorption[37,103]. 
Magnesium is one of the most prevalent intracellular 
cations, secondary only to potassium. It has been de-
monstrated that chronic alcohol consumption impairs 
magnesium homeostasis affecting the brain, skeletal 
muscles, heart, and liver[107]. In addition, alcohol abuse 
can decrease nutritional intake and increase excretion 
of magnesium by an indirect effect on renal tubules[107]. 
Other factors that might lead to hypomagnesemia in 
cirrhotic patients are the poor absorption of magnesium 
in the distal jejunum, exacerbation of magnesium urinary 
excretion due to elevated aldosterone, growth hormone, 
and glucagon blood levels, and chronic administration of 
loop diuretics[108]. The association between magnesium 
serum levels and the presence of cirrhosis or its severity 
is questionable. Two studies have found that magnesium 
concentration was not significantly different between 
patients with and without liver cirrhosis and no significant 
correlation was found with the Child-Pugh score[109,110]. 
One study found magnesium levels were significantly 
lower in cirrhotic patients compared to controls, but 
there was no difference between compensated and de-
compensated patients[111]. Conversely, another study 
demonstrated a negative correlation between serum 
magnesium and Child-Pugh score, and lower levels of 
magnesium among patients with cirrhosis compared 
to controls[112]. This disagreement can result from the 
different disparity of etiologies for the liver disease. 
Nangliya et al[112] reported that the prevalence of alcoholic 
liver disease was over 40%, however, Agarwal et al[110] 
excluded chronic alcohol abuse. Another explanation is 
that magnesium is a cellular cation and perhaps its serum 
level does not reflect its true concentration. Koivisto et 
al[113] argued that serum magnesium concentrations 
may be normal despite intracellular depletion and that 
a true estimation of magnesium depletion is through a 
magnesium loading test, since magnesium uptake is 
increased in the condition of magnesium depletion. In 
their study, 10 cirrhotic patients were compared to six 
healthy controls. No difference was found between pre-
loading magnesium levels, but the uptake of magnesium 
(calculated as the delta between the IV administered 
dose and the amount excreted in 24-h urine) was more 
than four-fold higher among cirrhotics compared to 
controls[113]. Due to scarce data and conflicting evidence, 
there are no clear clinical practice recommendations 
regarding magnesium supplementation in cirrhotic 
patients. 
While all patients with chronic liver disease are at 
risk for depletion of various fat-soluble, water-soluble 
vitamins and trace elements, the most well-recognized 
micronutrient deficiencies related to alcohol overuse 
are vitamin B12 (cyanocobalamin), vitamin A, vitamin 
D, thiamine (B1), folate (B9), pyridoxine (B6), and 
zinc[114,115]. Following supplementation, when needed, an 
annual check-up once stable levels are achieved may be 
recommended[116]. Administration of B-complex vitamins 
such as thiamine, folate, and pyridoxine is needed 
to prevent Wernicke encephalopathy[114], Korsakoff’s 
syndrome, megaloblastic anaemia and neuropathies[116]. 
Moreover, and regardless of the etiology of cirrhosis, 
a consensus paper by the International Society for 
Hepatic Encephalopathy and Nitrogen Metabolism 
stated that since vitamin status is not easily assessed 
and since multivitamin supplementation is cheap and 
generally safe, use of short-term (2-wk course) oral 
vitamin supplements could be justified in patients with 
decompensated cirrhosis or at risk of malnutrition, and 
clinically apparent vitamin deficiencies should be treated 
specifically[117].
PROTEIN AND CALORIE INTAKE 
IN PATIENTS WITH OBESITY AND 
CIRRHOSIS
Decreased muscle mass and function are more pre-
valent among cirrhotic patients with either MHE or 
OHE compared to no HE, and protein malnutrition is 
an independent risk factor for both OHE (OR = 3.4; 
95%CI: 1.4-6.9; p < 0.001) and MHE (OR = 2.15; 
95%CI: 1.1-4.1; p = 0.002)[118]. In the late 90s, the 
recommendations for caloric intake were near-normal 
for patients with well-compensated liver cirrhosis 
[25-35 kcal/(kg•d)] and up to 30-40 kcal/(kg•d) in 
malnourished or critically ill cirrhotic patients[119]. The 
ESEPEN currently recommends a daily caloric intake of 
35-40 kcal/(kg•d) for all cirrhotic patients regardless 
of their liver disease etiology or degree of liver function 
compensation[120], without a specific reference for cirrhotic 
patients with obesity, which may still be malnourished. 
However, weight loss should be encouraged in pa-
tients with obesity and well-compensated cirrhosis, 
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nevertheless, over-restriction will result in endogenous 
muscle breakdown. Indeed, in later guidelines, Amodio et 
al[117] recommend careful monitoring alongside increased 
physical activity and caloric intake of 25-35 kcal/(kg•d) in 
patients with obesity (30-40 kg/m2) and not less than 
20-25 kcal/(kg•d) in patients with morbid obesity (> 
40 kg/m2). The recommended dietary pattern is for 
small, frequent meals evenly distributed throughout the 
day (every 3-6 h) with a late evening snack containing at 
least 50 g of complex carbohydrate[117]. 
The attitude toward daily protein intake has also 
changed. In the past, the daily protein intake of cir-
rhotic patients was tightly restricted to less than 
0.8 g/(kg•d) due to concerns about the increased risk 
for HE. However, the tolerance of proteins in cirrhotic 
patients has been shown to be higher than previously 
believed[117,121], and the importance of substantial daily 
protein intake for sustaining adequate muscle mass 
is becoming more and more clear[117]. Córdoba et 
al[121] showed that administration of a low-protein diet 
[0.5 g/(kg•d)] worsened HE and exacerbated protein 
breakdown compared to a daily protein intake of 1.2 
g/(kg•d).
Currently, the recommended daily protein intake is 
1.2-1.5 g/(kg•d)[120]. For cirrhotic patients with obesity, 
a moderately hypocaloric diet must include an adequate 
amount of proteins [1.2-1.5 g/(kg•d)] in order to ac-
complish weight loss without muscle or lean mass dep-
letion[117]. In cirrhotic patients, there is variable tolerance 
to different dietary proteins according to their source. 
Some uncontrolled studies have shown a better tolerance 
to vegetable proteins over meat proteins and to dairy 
proteins over mixed source proteins[122-124]. Interestingly, 
a 14-d casein-vegetable, high-protein, high-calorie 
diet was shown to improve mental performance and 
to decrease ammonia levels in 150 patients with overt 
HE[125]. The advantages of vegetable proteins may stem 
from the fact that they are rich in dietary fiber with 
prebiotic properties, which result in decreased transit 
time and intraluminal pH leading to increased fecal 
ammonia excretion. Moreover, vegetable proteins are rich 
in ornithine and arginine, that can facilitate clearance of 
ammonia through the urea cycle[126,127]. Vegetable-protein 
based diets can also be beneficial in terms of caloric and 
fiber intake among overweight patients with cirrhosis 
who are attempting to lose weight. In addition, plant-
based proteins are rich in branched-chain amino acids 
(BCAA)[117,128,129]. In hepatic decompensation, there is a 
shift toward aromatic amino acids (AAA) (phenylalanine, 
tyrosine, and tryptophan) rather than BCAAs (isoleucine, 
leucine, and valine), however, AAA are assumed to cross 
the blood-brain barrier, act as false neurotransmitters, 
and induce HE[130,131]. BCAA supplementation can induce 
tolerability to meat protein and enable adequate protein 
intake[132]. Moreover, substituting meat with dairy or 
vegetable proteins along with BCAA supplements is 
better than reducing total proteins intake[117]. In a 
meta-analysis of 16 RCTs, BCAAs were found to have 
a beneficial effect on HE compared to placebo or best 
supportive care (diet, lactulose, or neomycin), however, 
no conclusions could be drawn regarding nutritional 
effects[133]. General nutritional recommendations in the 
cirrhotic patients with obesity are summarized in Table 2.
BARIATRIC SURGERY-INDUCED WEIGHT 
LOSS IN PATIENTS WITH OBESITY 
AND CIRRHOSIS: INDICATIONS AND 
CONTRAINDICATIONS
In recent years, parallel to the rapid and sharp increase 
in the prevalence of obesity[134], bariatric surgery has 
reached a rapid and deep penetration, as it is the 
only therapeutic means leading to long-term weight 
loss with consequent improvement of obesity-related 
comorbidities and patients’ quality of life[135]. NAFLD has 
become an extremely frequent condition in recent years 
due to the obesity epidemic[136]. While NAFLD includes 
a spectrum of histologic features ranging from simple 
liver steatosis to steatohepatitis (NASH), liver fibrosis 
has been shown to be the main determinant of mortality 
linked to NASH in the long-term[137,138]. Obesity has been 
shown to be associated with an increased risk of primary 
liver cancer in several large epidemiological studies. 
Potential mechanisms responsible for this increased risk 
include the occurrence of NAFLD and type 2 diabetes[139]. 
Furthermore, there is evidence that the probability of 
clinical decompensation of liver cirrhosis is significantly 
Nutrient Recommendation
1Daily energy intake[117] 25-35 kcal/(kg•d) in patients with BMI 30-40 kg/m2
20-25 kcal/(kg•d) in patients with BMI > 40 kg/m2
2Protein intake[119] 1.2-1.5 g/(kg•d)
3Micronutrients Identify and correct micronutrient deficiencies
Fiber 25-45 g/d
Table 2  Nutritional recommendations for cirrhotic patients with obesity
1The recommended dietary pattern is for small, frequent meals evenly distributed throughout the day (every 3-6 h) with a late evening snack containing at 
least 50 g of complex carbohydrate. 2Vegetable-protein based diets can also be beneficial in terms of caloric and fiber intake among overweight patients with 
cirrhosis who are attempting to lose weight. In addition, plant-based proteins are rich in branched-chain amino acids (BCAA)[117,127,128]. 3Cirrhotic patients 
with obesity are at high risk for depletion of various fat-soluble, water-soluble vitamins and trace elements and should be supplemented appropriately. 
BMI: Body mass index.
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increased in the presence of obesity compared to 
overweight and lean subjects[140].
As a consequence, LT surgeons are faced more and 
more frequently with candidates for LT with morbid 
obesity[141]. Traditionally obesity has been considered 
a main risk factor for postoperative morbidity and mor-
tality in the context of major and complex surgical pro-
cedures[142,143]. However, obesity is a heterogeneous 
disease including different conditions sharing a common 
denominator represented by an increased BMI. Indeed, 
there is clear epidemiological evidence that the presence 
of obesity has a protective effect against postoperative 
mortality and morbidity in the range of BMI below 
35 kg/m2. This phenomenon, known as the obesity 
paradox, has been attributed to the increased reserve 
of energy due to obesity that may confer an advantage 
in a condition of stress such as that after a major sur-
gical procedure[144]. Furthermore, the presence of meta-
bolic syndrome, which is associated with obesity but 
not obesity alone, is significantly associated with an 
increased risk of postoperative morbidity and mortality 
after major abdominal surgery. In spite of this, in many 
LT centers the presence of obesity, defined only on the 
basis of a BMI above 35 or 40 kg/m2, is considered as 
a contraindication to LT[145]. Interestingly, the use of 
simple diagnostic tools such as anthropometric measures 
that include the psoas muscle diameter and visceral 
fat measure coupled with the presence of metabolic co-
morbidities may help to identify suitable candidates for 
LT among individuals with obesity without the need for 
massive weight loss[146,147].
Losing weight before LT remains an important goal 
but there is no consensus on how best to achieve it, 
especially in patients with obesity and cirrhosis. Many 
non-surgical methods can be used to allow patients 
to reach the desired BMI and be finally listed for LT, 
including increased physical activity, diet, and behavioral 
therapy as well as intragastric balloon[33]. Spengler et 
al[33] recently suggested the use of diet and lifestyle 
modifications in patients with compensated cirrhosis. For 
patients with compensated cirrhosis, bariatric surgery 
has also been proposed in preparation for LT[145-147]. 
Although this strategy may seem legitimate, bariatric 
surgery may lead to severe postoperative complications 
that a patient with a compromised liver function may 
not tolerate. Indeed, only patients with compensated 
cirrhosis are potential candidates for bariatric surgery as 
mortality in patients with decompensated cirrhosis would 
be inacceptable[148]. There is also evidence that bariatric 
surgery is associated with a significantly lower morbidity 
and mortality if an LT program is also present in the 
same hospital. This underlines the complexity of the 
patients that need multidisciplinary care from specialists 
in both hepatology and bariatrics.
The timing of surgery 
The timing of bariatric surgery in LT candidates is im-
perative. While it has been suggested that bariatric 
surgery-induced weight loss may increase the candidacy 
for LT, only patients with compensated liver cirrhosis are 
potential candidates to bariatric surgery because the risk 
of mortality is too high in the setting of decompensated 
cirrhosis[148]. The primary indication for LT in patients 
with a conserved liver function is represented by HCC. 
While international guidelines for access to bariatric 
surgery include a disease-free interval of at least five 
years after the radical treatment of any malignancy, a 
different strategy to access a curative treatment such 
as LT for this specific category of patients seems to be 
legitimate. Only patients with the best chances of long-
term survival should then be selected for this ambitious 
therapeutic strategy, which includes bariatric surgery to 
lose weight and control metabolic comorbidities followed 
by LT. Endovascular and/or percutaneous interventional 
radiology techniques should be concomitantly used to ob-
tain temporary local control of HCC.  Several preoperative 
scores such as the alpha-fetoprotein score[149], the Milan 
criteria, and Metroticket 2.0 may be useful tools to guide 
the selection of patients in order to obtain long-term 
survival rates after LT comparable to those obtained for 
patients with non-tumoral disease[150].
The option of performing bariatric surgery after LT 
offers several advantages including normal liver func-
tion with normal prothrombin time, the restoration of 
normal portal pressure, the possibility to optimize the 
nutritional status and the choice of procedure in relation 
to the presence or absence of metabolic syndrome. The 
presence of adhesions linked to transplantation is not a 
formal contraindication to the laparoscopic approach nor 
is the use of immunosuppressive drugs[151].
As obesity recurs often after LT, affecting the 
graft with NASH recurrence and patient survival with 
metabolic comorbidities, some authors evoked the se-
ducing possibility of performing a bariatric procedure, 
namely sleeve gastrectomy (SG), at the same time as the 
LT[152]. However, a panel of argument still stands against 
this policy, these include: the potentially disastrous 
consequences of the most feared complication of SG, 
a leak at the top of the staple line in the setting of im-
munosuppressive treatment in a freshly transplanted 
patient; the reduced amount of calories that the trans-
planted patient would be able to assume with the diet 
spontaneously for several months after surgery; the 
impact of the two procedures on the body composition 
with the risk of excessive fatty free mass loss.
The choice of procedure
The presence of portal hypertension may render any 
bariatric procedure difficult and lead to life-threatening 
bleeding. The choice of the procedure should then 
take into account the risk of bleeding. A transjugular 
intrahepatic portosystemic shunt (TIPS) may be con-
sidered in patients with signs of portal hypertension such 
as platelets below 100000, a large spleen on CT scan, 
the presence of collateral circulation on the abdomen or 
on CT scan and esophageal varices. In case of doubt, 
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a direct measure of the portal pressure should be ob-
tained. It should be considered that in the case of large 
spontaneous portosystemic shunts (larger than 1 cm), 
the TIPS might be inefficacious. The possibility to access 
the biliary tree endoscopically after LT should also be 
considered. Procedures with an intestinal bypass definitely 
limit the endoscopic access to the bile duct. Furthermore, 
some patients may need a biliodigestive reconstruction 
on a Roux-en-Y loop that should be then fashioned in 
addition to the intestinal bypass of the bariatric pro-
cedure. There is a risk of portal vein thrombosis in any 
abdominal procedure and bariatric surgery has been 
shown to increase this risk. The potential risk of liver 
complications due to the intestinal bypass is another 
point that needs attention. It is well recognized that 
bariatric procedures including an intestinal bypass may 
lead to liver failure. Although the mechanisms underlying 
this complication have not been completely elucidated, 
the abnormal intestinal microbiota derived from bacterial 
overgrowth may cause intestinal permeability defects 
that expose hosts to noxious gut-derived factors such 
as bacterial lipopolysaccharide, other toll-like receptor 
ligands, and toxic bile acids[153]. Interestingly, most, if 
not all, cases of liver failure reported in the literature 
include patients with a biliopancreatic diversion, in which 
the length of the bypassed intestine is very long, and 
the jejuno-ileal bypass, whereas only a few cases of 
liver failure in patients with Roux-en-Y gastric bypass 
(RYGP) have been reported[154]. The jejuno-ileal bypass 
was proscribed several decades ago and nowadays the 
Scopinaro’s procedure is rarely performed. This is in line 
with the hypothesis that an altered microbiota may be 
a major determinant of increased intestinal permeability 
as the more distal is the bypass the more altered is the 
intestinal flora.
The absorption of immunosuppressive drugs should 
also be considered when choosing the most appropriate 
bariatric procedure. The absorption of drugs may not 
only be altered by the presence of an intestinal bypass 
but also by the changes in the intestinal pH linked to the 
suppression of hydrochloric acid secretion[155]. Finally, the 
etiology of liver disease (namely NASH vs viral infections 
and alcohol abuse), the presence of metabolic syndrome, 
and NASH recurrence on the graft in cases of patients 
that have already been transplanted are key factors to 
consider when choosing the type of bariatric procedure.
The three most common bariatric procedures cur-
rently performed worldwide are laparoscopic adjustable 
gastric banding (LAGB), the SG, and RYGP. Several 
factors are involved in the choice of the bariatric pro-
cedure in the setting of LT (Table 3). Although the LAGB 
has the advantage of being the easiest procedure with 
the lowest risk of bleeding, it also has the worse results 
in terms of weight loss with the highest rate of failure. 
Furthermore, the presence of foreign material around 
the mesogastric junction, especially in patients with 
esophageal varices, may cause problems. The SG is 
currently the most performed procedure[156,157] that 
offers several advantages, including the fact that no 
intestinal bypass is done, leaving the whole digestive 
tract accessible to endoscopic exploration, avoiding 
intestinal bypass related interference with the absorption 
of immunosuppressive drugs, and leaving the possibility 
to fashion a Roux-en-Y loop in the event of biliary com-
plications after LT or in cases where a biliodigestive 
reconstruction is indicated such as in primary biliary 
cholangitis. However, in cases of portal hypertension, 
the division of the greater curvature vessels may expose 
to the risk of bleeding especially if portal pressure is 
increased and no TIPS has been put in place. Bleeding 
may be then difficult to control and should be feared as 
a life-threatening complication. The use of buttressing 
material for the division of the stomach may reduce 
significantly the risk of bleeding in these patients and 
should be used[158].
Of note is also the fact that the SG is followed by an 
extreme decrease in hydrochloric acid secretion, resulting 
in an altered pH, which may consequently interfere 
with immunosuppressive drug absorption[155]. Although 
short and medium-term results of SG on weight loss 
and control of metabolic syndrome indicate equivalent 
efficacy between the SG and the RYGP[159], long-term 
results of SG are still too scarce to drive definite con-
clusions on the equivalence of efficacy between the two 
procedures, especially in a NASH setting[160]. 
The RYGP has the advantage of a reduced risk of 
bleeding, as only the lesser curvature of the stomach, 
where bleeding may occur, needs to be dissected before 
gastric division. It is also more effective against metabolic 
complications of obesity that may be either present 
before or after LT[161]. Strong evidence in support of the 
preventive effect of RYGP against the occurrence of type 
Factors to consider SG RYGB
Bleeding risk of bleeding1 Increased Low
Endoscopic access to the biliary tree Conserved Impossible
Risk of portal vein thrombosis Increased Not affected
Risk of bariatric surgery induced liver failure Absent Low
Absorption of immunosuppressive drugs Poorly affected Decreased
Etiology of liver cirrhosis (NASH vs others) Effective Very Effective
Table 3  Main factors involved in the choice of the bariatric procedure in the setting of liver transplantation
1Consider measuring of portal pressure and use of transjugular intrahepatic portosystemic shunt in case of bariatric surgery before liver transplantation. 
SG: Sleeve gastrectomy; RYGP: Roux-en-Y gastric bypass; NASH: Non-alcoholic steato hepatitis. 
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2 diabetes has come from several studies[162,163]. Recently 
Safwan et al[164] reported a series of 11 patients with 
a previous history of bariatric surgery that underwent 
LT and showed that biliary complications could be suc-
cessfully addressed with a second Roux-en-Y loop in 
patients with an RYGP. One additional technical point 
concerns the use of the endoluminal tube to guide the 
shaping of the gastric pouch or sleeve. If the preoperative 
endoscopy has shown the presence of esophageal 
varices, in spite of appropriate endoscopic eradication, 
the orogastric tube may eventually injure the varices 
causing bleeding. For this reason, it should be better 
avoided as far as possible especially in patients with 
a low prothrombin time and platelet count. SG is also 
associated with an increased risk of portal thrombosis 
compared to RYGP in non-cirrhotic patients[165]. This may 
be a further concern, as liver cirrhosis is a risk factor 
for portal thrombosis in itself. The occurrence of portal 
thrombosis may further complicate the access to LT. 
The risk of dumping syndrome and hyperinsulinemic 
hypoglycemia may be further concerns of the RYGP.
In conclusion, with all of the potential that bariatric 
surgery has candidates to LT with morbid obesity, well-
designed studies are still necessary to gain widespread 
acceptance from clinicians. Several points need to be 
clarified, including the most appropriate methods for 
accurate patient evaluation and selection, the optimal 
surgical procedure and its timing to maximize the efficien-
cy of bariatric surgery in liver recipients with obesity. Only 
when this research is furthered to the point where the 
effectiveness of bariatric surgery is no longer in doubt, 
the latter will be included in the care of liver recipients 
with obesity for mainstream use. In the meantime, the 
policy of a case-by-case discussion involving a multi-
disciplinary team, including hepatologists and both LT 
and bariatric surgeons, seems to be justified.
CONCLUSION
With the recent epidemic of obesity, the coexistence of 
liver cirrhosis and obesity has become very frequent. 
The complex interplay between obesity and the liver 
especially in the setting of liver cirrhosis is a formidable 
challenge for current medicine that goes from the 
prevention of liver complications of obesity, screening 
for these complications in patients at risk to the man-
agement of patients with sarcopenia and end-stage liver 
disease. Bariatric surgery has shown promising results 
although evidence is still scarce. 
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